ASCO submitted comments to congressional committees regarding the Food and Drug Administration (FDA) Reauthorization Act, which Congress expects to take up before the current authorization expires on September 30, 2017.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO participated in the Childhood Cancer Action Day, where more than 200 advocates met with policymakers to discuss key legislation that would improve research and treatment for pediatric cancer.
On May 10, 2017, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA® , Merck and Co., Inc.) in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC).
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, and the College of American Pathologists (CAP) announced today that they will be partnering to bolster the expertise being provided to the CancerLinQ® platform, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.
On May 9, 2017, the U.S. Food and Drug Administration granted accelerated approval to avelumab (BAVENCIO® , EMD Serono, Inc.) for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
ASCO has joined a coalition of more than a dozen specialty societies in supporting an effort in the U.S. House of Representatives to relieve the significant administrative burdens and financial penalties slated to be imposed on physicians in 2018 as part of the Medicare physician fee schedule (MPFS)—due to be released this summer. ASCO is concerned about the impact these burdens could have on patient care since oncologists would have to juggle the requirements of multiple Medicare quality improvement programs in addition to time spent providing patient care.
On May 4, the U.S. House of Representatives passed H.R. 1628, the "American Health Care Act" (AHCA), in a 217-213 vote. The bill would repeal and at least partly replace the Affordable Care Act if signed into law.
The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in the United States every year, millions of individuals with cancer and their families rely on the FDA to provide critical oversight and evaluation of the safety and efficacy of new medical products as well as those in routine clinical use.
ASCO has released findings from an ASCO-National Cancer Institute (NCI) collaboration that explored centralizing the development of coverage analyses for multi-site cancer clinical trials. In an ASCO special article published May 8 in the Journal of Oncology Practice, “Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute,” the authors assert that developing a centralized system for coverage analysis is a feasible way to address key issues and reduce administrative burdens for cancer research sites managing billing compliance, with potential for widespread benefits across the cancer research field.
ASCO was on Capitol Hill with the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) to advocate for robust federal research funding.
CancerLinQ LLC, a wholly-owned nonprofit of ASCO, has announced a partnership with the Oncology Nursing Society (ONS). CancerLinQ will draw on ONS's expertise and thought leadership as it continues to provide a robust quality improvement and data-sharing platform to oncology practices and cancer centers. The collaboration builds on the CancerLinQ® Ambassadors Program, which the two organizations launched earlier this year
ASCO applauds members of the House and Senate for their vote this week to provide a $2 billion increase in funding to the National Institutes of Health (NIH). This marks the first time in more than a dozen years that Congress has provided the NIH with a back-to-back funding increase.
Registration is now open for the ASCO Research Community Forum 2017 Annual Meeting, which will be held September 24-25, 2017 at ASCO headquarters in Alexandria, Va. The theme of this year’s meeting is advancing cancer care through research partnerships.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of the ASCO®, has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform.
On April 20, Tracey Weisberg, MD, chair of ASCO’s State Affiliate Council, testified on behalf of the Northern New England Clinical Oncology Society (NNECOS) and ASCO before the Maine Joint Standing Committee on Health and Human Services. Dr. Weisberg’s testimony expressed strong support for LD 273, legislation that would add a cancer exception to Maine’s prescription monitoring program requirements. In her testimony, Dr. Weisberg also advocated for LD 1031, which would add a cancer exception to opioid prescription limits in the state.